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Abstract
Background Doxylamine succinate, an ethanolamine-
based antihistamine, is used in the short-term management
of insomnia because of its sedative effects. No data on the
dose proportionality of the pharmacokinetics of doxyla-
mine are available, although this drug has been marketed in
European countries for more than 50 years.
Objective The objective of this study was to evaluate and
compare the dose proportionality between two marketed
strengths (12.5 mg and 25 mg) of doxylamine hydrogen
succinate after a single oral dose administration under
fasting conditions in healthy human subjects.
Study Design This was a single-center, randomized, sin-
gle dose, laboratory-blinded, two-period, two-sequence,
crossover study.
Setting The study was conducted in a phase I clinical
unit.
Subjects and Methods A single oral dose of doxylamine
hydrogen succinate of 12.5 mg (equivalent to 8.7 mg of
doxylamine base) or 25 mg (equivalent to 17.4 mg of
doxylamine base) was administered to healthy volunteers
under fasting conditions in each study period. The drug
administrations were separated by a wash-out period of 7
calendar days. Blood samples were collected for up to 60 h
post-dose, and plasma doxylamine levels were determined
by an ultra high-performance liquid chromatography
method with tandem mass spectrometry detection. Phar-
macokinetic parameters were calculated using non-com-
partmental analysis. Dose proportionality was assessed
based on the parameter area under the concentration–time
curve (AUCt normalized). Safety was evaluated through
assessment of adverse events, standard laboratory evalua-
tions, vital signs and 12-lead electrocardiogram (ECG).
Results In total, 12 healthy volunteers (3 male; 9 female)
were included in the study. Mean maximum observed
plasma concentration (Cmax) and area under the concen-
tration–time curve from time zero to time t (AUCt) of
doxylamine hydrogen succinate 12.5 mg and 25 mg tablets
increased linearly and dose-dependently [12.5 mg: mean
Cmax 61.94 ng/mL, coefficient of variation (CV) 23.2 %;
mean AUCt 817.33 ngh/mL, CV 27.4 %; and 25 mg:
mean Cmax 124.91 ng/mL, CV 18.7 %; mean AUCt
1630.85 ngh/mL, CV 22.8 %]. Mean AUCt normalized was
815.43 ngh/mL, CV 22.8 % for 25 mg. The dose-nor-
malized geometric mean ratio (%, 12.5 mg/25 mg) of
AUCt was 98.92 (90 % CI: 92.46, 105.83). The most
common adverse event was somnolence.
Conclusions Exposure to doxylamine was proportional
over the therapeutic dose range of 12.5–25 mg in healthy
volunteers. Based on the results, a predictable and linear
increase in systemic exposure can be expected. Doxyla-
mine hydrogen succinate was safe and well tolerated.
1 Introduction
Doxylamine succinate, an ethanolamine-based antihista-
mine, shares the actions and uses of other antihistamines.
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Because of its sedative effect, doxylamine medicinal
products (alone or in combination with other drugs) have
been authorized for more than 50 years with an appropriate
extent of use for short-term management of insomnia
[1–5]. Currently, it is a medical product with a legal base of
well-established use in Europe.
Based on clinical practice, the recommended adult dose
for doxylamine hydrogen succinate as a nighttime sleep aid
is 25 mg, once daily, taken orally up to half an hour before
bedtime. If drowsiness is excessive, the dosage should be
reduced to 12.5 mg. Doses higher than 25 mg are not
recommended. Dormidina has been marketed in Spain
since 1990 with a unique active ingredient: doxylamine
hydrogen succinate, 12.5 mg or 25 mg. Because its mar-
keting authorization was approved before the implemen-
tation of the present regulatory standards, a new
pharmacokinetic study of doxylamine hydrogen succinate
in its current pharmaceutical presentation (film-coated
tablets) has been recently published [6]. This study pro-
vides updated data on the pharmacokinetic parameters of
doxylamine following a 25 mg dose in both fasting and fed
conditions. The results indicate that the kinetic parameters
of doxylamine were not affected by a high-fat, high-calorie
food intake, and the drug was safe and well tolerated by the
subjects. Furthermore, no differences between genders
were observed [6].
No data on the dose proportionality of doxylamine were
available. Therefore, the main objective of this study was
to evaluate and compare the bioavailability with regard to
dose proportionality between the two marketed strengths
(12.5 mg and 25 mg) of doxylamine hydrogen succinate
film-coated tablets after a single oral dose administration
under fasting conditions in healthy subjects.
2 Subjects and Methods
2.1 Study Design
This was a single-center, randomized, single-dose, labo-
ratory-blinded, two-period, two-sequence, crossover study.
A single oral dose of doxylamine hydrogen succinate,
12.5 mg (Dormidina, equivalent to 8.7 mg of doxylamine
base) or 25 mg (Dormidina, equivalent to 17.4 mg of
doxylamine base), was administered under fasting condi-
tions in each study period. Since the Physician’s Desk
Reference rates doxylamine as being in pregnancy category
B, it was acceptable to include women in the present study.
To ensure that no carryover effect was observed, a wash-
out period of 7 calendar days was observed between drug
administrations, corresponding to more than 10 times the
expected half-life of the moiety to be measured. It should
be noted that the randomization code was not made
available to the personnel in charge of the determination of
plasma drug concentrations (Bioanalytical and Develop-
ment ADME Department, Laboratorios del Dr. Esteve,
S.A., Barcelona-Catalonia) until results were audited by the
quality assurance department.
The protocol and the informed consent forms were
approved by an independent review board (ETHIPRO) on
27 September 2012. All subjects voluntarily agreed to
participate in this study and signed the informed consent
form after having fully comprehended its contents and
prior to initiation of study procedures. This study was
performed in compliance with Good Clinical Practice [7].
2.2 Study Population
Subject screening procedures included informed consent,
inclusion/exclusion check, demography, medical history,
medication history, physical examination, height, weight,
body mass index and a concomitant medication check.
Subjects were in good health as determined by a medical
history, physical examination (including vital signs), elec-
trocardiogram (12-lead ECG) and the usual clinical labo-
ratory tests (hematology, biochemistry, urinalysis)
including negative HIV, hepatitis B and hepatitis C tests,
negative screening for ethanol and drugs of abuse in urine
and negative pregnancy test (for female subjects).
All participating subjects were judged to be eligible for
the study when assessed against the inclusion and exclusion
criteria. Tolerability and safety were evaluated through
assessment of adverse events (AEs), standard laboratory
evaluations and vital signs.
The predetermined reason for removing subjects from
the study was for any safety issues as determined by the
investigator. Also, subjects could be withdrawn because of
protocol violations, administrative problems, difficulties in
blood collection, occurrence of emesis during the time
interval described in the protocol or other reasons descri-
bed in the protocol. Furthermore, subjects were allowed to
discontinue their participation in the study at any time. In
the event of such a discontinuation, the subject was
requested to complete a safety assessment at the time of
discontinuation, and the reason for discontinuation was to
be documented.
2.3 Blood Sample Collection; Method of Measurement
Blood samples were collected into tubes containing K2-
EDTA prior to and 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 3.5,
4, 5, 6, 8, 12, 16, 24, 36, 48 and 60 h after drug adminis-
tration. This sampling was planned in order to provide a
reliable estimate of the extent of absorption, as well as the
terminal elimination half-life, and to ensure that the area
under the plasma concentration–time curve (AUC) from
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time zero to time t (AUCt) was at least 80 % of the AUC
from time zero extrapolated to infinity (AUC?). Samples
were processed and stored under conditions (frozen) that
have been shown not to cause significant degradation of the
analyte.
The experimental samples were assayed for doxylamine,
using a validated bioanalytical ultra-high-performance
liquid chromatography method with tandem mass spec-
trometry detection (UPLC/MS/MS method, Xevo TQ MS,
Waters Corp., Milford MA), which involved the solid-
phase extraction of doxylamine and the deuterium-labeled
internal standard (Doxylamine-d5) from plasma samples
(150 lL). The calibration curve ranged from 1.0 to
300.0 ng/mL and the limit of quantification was 1.0
ng/mL. A gradient elution with 0.1 % formic acid in ace-
tonitrile and 0.1 % formic acid in water was used for the
mobile phase. A volume of 10 lL was injected into an
Acquity UPLC BEH C18 column (1.7 lm particle size,
2.1 mm id 9 50 mm length) and the transitions (m/z) for
both doxylamine (271.22/167.02) and internal standard
(276.24/171.28) were monitored using MRM ion mode
ESI?.
The parameters evaluated during the validation were
linearity and range, selectivity including hemolysed and
hyperlipidemic plasma, specificity in the presence of
common OTC, intra- and inter-run precision and accuracy,
limit of quantification, dilution integrity, carryover,
recovery, matrix effect, stock solution stability, autosam-
pler stability, short-term stability in human plasma at room
temperature, freeze-thaw and long-term stability in human
plasma. All the evaluated parameters met the acceptance
criteria of the current guidelines.
For past analytical batches run during the validation, the
precision expressed as %CV of calibration standards ran-
ged from 0.8 to 3.7 %, and the % mean accuracy of the
back-calculated value of the calibration standards ranged
from 94.2 to 103.4 %. The mean correlation coefficient for
these analytical batches was 0.9992.
The intra-run precision expressed as %CV for all con-
centration levels of quality control samples ranged from 0.9
to 12.7 %, and the inter-run precision ranged from 1.1 to
7.9 %. The intra-run accuracy expressed as % nominal for
all concentration levels of quality control samples ranged
from 96.4 to 113.7 %, and the inter-run accuracy ranged
from 102.8 to 108.8 %.
Each batch of test samples was analyzed together with a
set of calibration standards and quality control samples.
Quality control samples were prepared in blank plasma at
low, medium and high concentration of the calibration
curve. Acceptance criteria based on current guidelines
were used for each analytical batch. Batches not meeting
these acceptance criteria were rejected and the samples
repeated.
2.4 Treatments Schedule
Subjects received the investigational products—doxyla-
mine hydrogen succinate 12.5 mg (Dormidina 12.5-mg
film-coated tablets, Laboratorios del Dr. Esteve, S.A,
Barcelona, Spain) or doxylamine hydrogen succinate
25 mg (Dormidina 25-mg film-coated tablets, Laborato-
rios del Dr. Esteve, S.A, Barcelona, Spain)—at each period
of the study under fasting conditions according to the
randomization list. The randomization scheme was com-
puter generated.
Food was controlled and standardized during the hous-
ing period and for all subjects. Subjects fasted overnight for
at least 10 h prior to drug administration. A single dose of
the Investigational Product was thereafter administered
orally with approximately 240 mL of water at ambient
temperature. Fasting continued for at least 4 h following
drug administration, after which a standardized lunch was
served. A supper and a light snack were also served at
appropriate times thereafter, but not before 9 h after dos-
ing. Water was allowed ad libitum until 1 h pre-dose and
beginning 1 h from drug administration.
2.5 Statistical Analysis
2.5.1 Sample Size
Based on the result of a previous study, the intra-subject
variability of AUCt for this product is around 6.2 % [6].
Assuming the expected geometric mean ratio of dose-
normalized AUCt is within 95–115 %, to meet the
80–125 % bioequivalence range with a statistical power of
at least 80 %, it is estimated that the minimum number of
subjects required is 6. On the other hand, the minimum
number of subjects for a standard bioequivalence study
according to EMA’s guideline is 12. Therefore, it should be
sufficient for this study to include 12 healthy volunteers.
2.5.2 Statistical Comparison
Descriptive statistics were used to summarize adverse
events, safety results and demographic variables (age,
height, weight and BMI). Pharmacokinetic parameters such
as Cmax, the time to reach Cmax (tmax), AUCt, AUC?,
AUCt:AUC?, the elimination rate constant (ke) and elim-
ination half-life (t) were calculated for each strength
tested.
According to EMA’s Guideline on the Investigation
of Bioequivalence [8], dose proportionality in terms of
extent of exposure was assessed based on the parameter
AUCt normalized (i.e. dose-adjusted AUCt). Moreover, dose
proportionality in terms of rate of exposure was also
assessed using the parameter Cmax normalized. The natural
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logarithmic transformation of AUCt was used for all sta-
tistical inference using an Analysis of Variance (ANOVA)
model. The fixed factors included in this model were the
subject effect (nested within sequence), the treatment
received, the period at which it was given as well as the
sequence in which each treatment was received. Propor-
tionality was assumed if the 90 % confidence interval of
the dose-normalized geometric mean ratio of AUCt was
within the 80.00 to 125.00 % range.
The main absorption and disposition parameters [Cmax
(-tmax-), AUCt, AUC?, ke and t] were estimated using a
non-compartmental approach with a log-linear terminal
phase assumption. The trapezoidal rule was used to esti-
mate the area under the concentration–time curve, and the
terminal phase was estimated by maximizing the coeffi-
cient of determination estimated from the log-linear
regression model. They were not to be estimated for indi-
vidual concentration–time profiles, where the terminal
log-linear phase could not be reliably characterized. Fur-
thermore, the mean, median, minimal value, maximal
value, standard deviation and coefficient of variation were
calculated for plasma concentrations at each individual
timepoint and for all pharmacokinetic parameters.
Between-treatment comparisons were performed using the
ANOVA model mentioned above for all parameters except
tmax, which was analyzed using a non-parametric approach.
Statistical and pharmacokinetic analyses were generated
using Kinetic (version 9.01), an application developed




A total of 12 healthy volunteers were included (3 male, 9
female), with a median age of 43 years (range 28, 58),
weight of 66.1 kg (range 51.6, 96.3), height of 167 cm
(range 157, 184) and body mass index of 24.0 kg/m2 (range
20.2, 28.4). All (100 %) subjects were white, and all of
them completed the crossover design and received a single
oral dose of the assigned treatment on day 1 and day 8.
3.2 Treatment Compliance
All subjects took the study medication according to the
protocol. The investigational product was administered
under the supervision of the qualified investigator or his
designees. The film-coated tablet was to be swallowed
whole and was not to be chewed or broken. Following
administration of the drug, each subject’s hands and mouth
were checked in order to confirm the consumption of the
medication. The physician in charge remained at the clin-
ical site for at least the first 4 h following each drug
administration and remained available at all times during
the entire period of the study.
3.3 Pharmacokinetic Assessments
Table 1 depicts the doxylamine pharmacokinetic results:
Cmax, tmax, AUCt, AUCt normalized, AUC?, AUCt:AUC?, ke
and t for both strengths of doxylamine hydrogen succi-
nate, and Table 2 shows the comparison results with
standards for bioequivalence. Proportionality was assumed
given that the 90 % confidence interval of the dose-nor-
malized geometric mean ratio of AUCt was within the
80.00 to 125.00 % range [98.92 % (90 % CI: 92.46,
105.83)]. No statistically significant between-treatment
differences were observed for the following parameters:
AUCt normalized, ln(AUCt normalized), AUCt : AUC?, tmax, ke
and t. Likewise, Cmax normalized was also calculated, and
the ratio between normalized doses was 101.45 (90 % CI:
96.17–107.01).
Figure 1 shows the linear profile of the mean ± standard
deviation (SD) plasma concentrations of doxylamine.
3.4 Tolerability and Safety
No deaths or serious AEs were reported during this study.
Eight (67 %) of the 12 subjects included in the study
Table 1 Summary of main pharmacokinetic parameters of
doxylamine





Cmax (ng/mL) 61.94 23.2 124.91 18.7
tmax (h)
a 1.67 32.0 1.67 25.2
AUCt (ngh/mL) 817.33 27.4 1630.85 22.8
AUCt normalized (ngh/
mL)b
817.33 27.4 815.43 22.8
ln(AUCt normalized)
b,c 6.6686 4.4 6.6795 3.5
AUC? (ngh/mL) 859.74 29.4 1697.58 25.2
AUCt:AUC? (%)
b 95.55 2.5 96.55 2.5
T (h)
b 12.23 30.7 12.45 19.9
a For tmax, the median is presented, and the range of tmax was
1.0–3.0 h for 12.5 mg and 1.0–2.5 h for 25 mg. The statistical anal-
ysis is based on a non-parametric approach (p C 0.05)
b The p value for the comparisons between the strengths was not
significant (i.e. p C 0.05), and the statistical analysis is based on a
parametric approach
c The standard deviation (SD) of ln(AUCt normalized) was 0.2938 for
12.5 mg and 0.2309 for 25 mg
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experienced a total of 13 AEs. Nervous System Disorders
(69 %) was the most commonly reported of the System
Organ Classes (SOCs).
After the administration of doxylamine hydrogen suc-
cinate 12.5 mg, three subjects (25 %) reported five AEs [2
different SOCs and 3 different MedDRA Preferred Terms
(PTs)]; after the administration of doxylamine hydrogen
succinate 25 mg, seven subjects (58 %) reported eight AEs
(2 different SOCs and 3 different MedDRA PTs). The
adverse events reported during the study were all of mild
severity. No moderate or severe adverse events were
observed during the study.
The most commonly reported AE of this study was
somnolence. Of the 13 AEs reported during the study, 6
subjects reported 8 occurrences of somnolence (62 %,
8/13): 2 subjects reported 2 occurrences following the
administration of doxylamine hydrogen succinate 12.5 mg
(17 %, 2/12) and 6 subjects reported 6 occurrences fol-
lowing the administration of doxylamine hydrogen succi-
nate 25 mg (50 %, 6/12), p = 0.083. The two subjects who
presented somnolence with the 12.5-mg dose also reported
the event with the 25-mg dose.
No significant alterations were found in the laboratory
evaluations and the electrocardiogram repeated at the end
of the study.
4 Discussion
This is the first time that the dose proportionality of the
pharmacokinetics of doxylamine hydrogen succinate in
film-coated tablets has been studied. According to EMA’s
Guideline on the Investigation of Bioequivalence [8], dose
proportionality is to be assessed based on the AUCt
parameter. The results of this study showed that the 90 %
confidence interval of the dose-normalized geometric mean
ratio of AUCt was within the range of 80 to 125 %. Con-
sequently, this result indicates that the two strength for-
mulations of doxylamine hydrogen succinate [12.5 mg
(Dormidina 12.5 mg film-coated tablets) and 25 mg
(Dormidina 25 mg film-coated tablets) exhibited linear
pharmacokinetics and that 12.5 mg and 25 mg of doxyla-
mine hydrogen succinate were dose proportional in healthy
subjects. Likewise, the pharmacokinetics of doxylamine
show relatively low intra-subject variability.
Updated data on the pharmacokinetic profile of doxyl-
amine in humans after an oral dose of doxylamine hydro-
gen succinate 25 mg in film-coated tablets have recently
been published [6]. As expected, the pharmacokinetic
parameters after an oral dose of doxylamine hydrogen
succinate 25 mg obtained in the present study were com-
parable to the ones in the abovementioned study [6].
Table 2 Standard s for comparative bioavailability of doxylamine
Parameter Intra-subject C.V. (%) Geometric Meana 12.5 mg/25 mg ratio (%) 90 % Confidence limits (%)
12.5 mg 25 mg Lower Upper
AUCt normalized 9.1 787.31 795.93 98.92 92.46 105.83
a Units are ngh/mL for AUCt normalized
Fig. 1 Linear profile of the
mean (±SD) doxylamine
plasma concentrations
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Likewise, the overall results of this study are in line with
studies performed with oral doses of 25-mg doxylamine
succinate tablets [5, 9, 10] and with oral doses of 20-mg
doxylamine succinate solution [11, 12].
Doxylamine hydrogen succinate is available as an over-
the-counter agent and is indicated for the symptomatic
treatment of occasional insomnia in adults of 18 years of age
and over. Overall, the two formulations tested (12.5- and
25-mg film-coated tablets) in this study were generally safe
and well tolerated. It should be noted that most of the subjects
reported somnolence mainly when administered the 25 mg
strength. In fact, 50 % (6 out of 12) of the subjects presented
somnolence when administered the 25-mg dose, but only
17 % (2 out of 12) with 12.5 mg. It is to be note that the two
subjects who presented somnolence with the 12.5-mg
strength also reported somnolence with the 25-mg dose.
Actually, in the case of doxylamine, somnolence has to be
considered as a pharmacodynamic effect associated with
clinical efficacy in the short-term management of insomnia.
Although this study was not designed to study the dose-pro-
portional effect of doxylamine on somnolence, this result
may suggest it. In clinical practice, the usual adult dose as
nighttime sleep aid is 25 mg once daily, taken 30 min before
bedtime. In fact, in clinical practice, the preponderance of
side effects associated with this dose is related to a carryover
to the next day of the hypnotic effects [13, 14]. This may be
experienced primarily as continued drowsiness, tiredness or
grogginess, ‘‘hangover’’ effect, sluggishness or lethargy.
Therefore, given that the two strength formulations (12.5 mg
and 25 mg) exhibited linear pharmacokinetics and since these
adverse events may be dose-dependent, in case of presenting
these symptoms, it is advisable to reduce the dose to 12.5 mg
or to take the dose earlier (more than 30 min) to ensure at
least an 8-h elapsed time before awaking.
Certain aspects of the study design should be considered
before drawing conclusions for future users of doxylamine
hydrogen succinate, as the open-label, single-dose design
and the fact that the study population consisted of healthy
subjects could lead to under- or overestimation of the
generalizability of the results beyond the population and
conditions that were studied. Likewise, the criteria used to
assess dose proportionality (only 2 strengths were tested to
study the dose-proportionality) could also lead to under- or
overestimation of the generalizability of the results. Nev-
ertheless, these two doses (12.5 mg and 25 mg of doxyla-
mine hydrogen succinate) represent the two approved
formulations commonly used in Spain.
5 Conclusion
Exposure to doxylamine was proportional over the thera-
peutic dose range of 12.5–25 mg in healthy volunteers with
a dose proportional increase in the overall amount of
doxylamine and its maximum concentration achieved. The
time to peak concentration in plasma was the same for the
12.5 and 25 mg doses of doxylamine hydrogen succinate.
Based on the results, a predictable and linear increase in
systemic exposure can be expected. Doxylamine hydrogen
succinate was safe and well tolerated.
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